We are delighted to announce that 27 innovative research projects have been awarded Peter Mac Foundation Grants in 2026, thanks to the generosity of Peter Mac Foundation supporters.
This year, we received a record number of 81 applications. Each went through a rigorous peer-review process to ensure funding is directed to the most innovative and high-impact projects. A total of $1.5m has been awarded to drive forward these promising new initiatives.
Peter Mac Foundation Grants provide seed funding to support pilot studies, giving researchers the momentum to establish new approaches to cancer treatment and care.
Excellence in Innovation Awards
The Foundation also awarded Excellence in Innovation Awards (an additional $5,000 each) to new investigators who received the highest scores across the peer review process, to support research activities and professional development opportunities, including conference attendance:
- Clinical - Dr Philippa Johnstone
- Laboratory - Dr Oguzhan Baltaci
- Health Services - Ms Stella Salpigtidis
- Allied Health - Mr Lachlan McIntosh
Full list of 2026 Peter Mac Foundation Grants recipients
- A/Prof Marliese Alexander - From Trial to Routine Care: Implementing the TARGET-TP Blood Clot Prevention Pathway in Cancer Care - a Pilot Implementation Study Using Co-Designed Strategies
- Dr Oguzhan Baltaci - Investigating tumour vasculature using a novel zebrafish brain cancer model
- Dr Elizabeth Christie - Multimodal profiling of circulating tumour & immune cells in gynaecological cancer
- Ms Catherine Devereux - Enhancing communication with patients and carers from culturally and linguistically diverse backgrounds.
- A/Prof Lisa Devereux - Yarning about cancer biobanking with Aboriginal and Torres Strait Islander Victorians
- Dr Andrea Di Pietro - Targeting the KLF4/IGF1R gene regulatory axis to overcome immunotherapy resistance in melanoma
- Dr Julia Dixon-Douglas - The Right Answer, Faster: Long-Read DNA Sequencing for Surgical and Treatment Decisions in Young Women with Breast Cancer
- Dr Elette Engels – MOTIVE: Multi-energy Optimised Treatment Investigation for Very high-energy Electrons
- Dr Mohamed Fareh - AI-designed protein binders to overcome drug resistance in cancer
- Dr Priscilla Gates - A feasibility study assessing longitudinal web-based cognitive assessment in patients with relapsed or refractory Large B-Cell lymphoma (LBCL) undergoing CAR (Chimeric Antigen Receptor) T-cell therapy
- Dr Glen Guerra - Investigating circulating tumour DNA (ctDNA) to guide patient selection for cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (CRS-HIPEC)
- A/Prof Nur-Shirin Harun - Multidisciplinary Immune Toxicity Service – a novel model of care for patients with immune-related adverse effects (irAEs)
- Dr Attila Horvath - Niche-dependent asymmetric chromatin inheritance drives therapy resistance in multiple myeloma
- Dr Philippa Johnstone - STRIDE-CRT: Structured pre-fraction Individualised Exercise programme During Chemoradiation — a pilot feasibility study in stage III non-small cell lung cancer
- A/Prof David Liu - Identifying novel drug targets and accelerating therapies to treat the spread of stomach and oesophageal cancers in the abdominal cavity
- Dr Thiago Maass Steiner – Harnessing CD4+ T cells to improve treatment responses in Diffuse Large B-cell lymphoma
- Dr Roberta Mazzieri – A First-in-Class LRRC15 Vaccine for Dual Targeting of Brain tumours and the Tumour Microenvironment
- Mr Lachlan McIntosh - Developing a novel total-body PET application for real-time verification of proton-beam therapy
- Dr Isabelle Munoz - Switching the Fuel: A Metabolic Reprogramming Strategy for CAR T Cells to Enhance Anti-Tumour Efficacy
- Dr Priyank Rawat - Epigenetic Reprogramming of Fusion Oncogenes as a Therapeutic Strategy for ALK-Fusion-Driven Cancers
- Dr Sarah Roth - Deciphering Immune Dysfunction in Retroperitoneal Liposarcoma
- Ms Stella Salpigtidis - Prevalence and characteristics of voice dysfunction associated with internal lymphoedema in head and neck cancer patients – a prospective observational study
- Dr Kevin Sek - Rewiring epigenetic regulation for precision armouring of CAR-T cells against solid cancers
- Dr Karen Slattery - Fuelling CAR T-cells with tumour nutrients to improve treatment of solid cancers
- Prof Ilia Voskoboinik - Improving the efficacy and safety of CAR T-cell therapy for T-cell acute lymphoblastic leukaemia.
- Dr Bonnita Werner - Decoding Reversion‑Mediated Resistance to PARP Inhibitors in High‑Grade Serous Ovarian Cancer
- Dr Wenxiao Kay Yue - Fluorine-18 CAIX-targeting peptides: enabling broad clinical access to theranostic-guided cancer care